Guardant Health, Inc. (GH)

Market Cap	20.52B +66.4%
Revenue (ttm)	1.28B +41.7%
Net Income	-485.07M
EPS	-3.68
Shares Out	135.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,293,355
Open	156.02
Previous Close	154.86
Day's Range	148.01 - 156.02
52-Week Range	74.55 - 191.05
Beta	1.66
Analysts	Strong Buy
Price Target	200.76 (+32.34%)
Earnings Date	Nov 5, 2026

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 2,506
• Stock Exchange: Nasdaq
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.

Analyst Summary

According to 26 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $200.76, which is an increase of 32.34% from the latest price.

Price Target

$200.76

(32.34% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 14, 2026

Data Sources Report a data error